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Acute lung injury (ALI) secondary to sepsis is one of the leading causes of death in sepsis. As such, many pharmacologic and
nonpharmacologic strategies have been employed to attenuate its course. Very few of these strategies have proven beneﬁcial. In
this paper, we discuss the epidemiology and pathophysiology of ALI, commonly employed pharmacologic and nonpharmacologic
treatments, and innovative therapeutic modalities that will likely be the focus of future trials.
1.Introduction
Acute lung injury (ALI) secondary to sepsis is the source of
substantial morbidity and mortality in both adult [1, 2]a n d
pediatric [3, 4] populations and is a major contributor to
intensive care unit (ICU) costs [5]. ALI and acute respiratory
distress syndrome (ARDS) are deﬁned by well-established
criteria (Table 1)[ 6] with sepsis and pneumonia being the
two leading etiologies [2, 3].
As ARDS is associated with a risk of mortality of 26–
44% in the adult population [1, 2] and 22% in the pediatric
population [7], a host of therapeutic strategies have been
attempted to alter the progression of ALI. While this review
will focus on the pharmacology of ALI in sepsis, it will also
provide brief summaries of nonpharmacologic treatment
strategies. ALI will be used to refer to both ALI and ARDS
unless treatments are speciﬁcally limited to patients with
ARDS.
2.Pathophysiology ofALIinSepsis
ALI, like sepsis, is a clinical description and common
endpoint of many pathophysiologic processes and should
be considered a syndrome and not a disease. In consid-
ering therapeutic strategies for ALI, clinicians attempt to
treat these common processes, address underlying etiologic
factors, and, when possible, tailor treatment to speciﬁc
underlying pathology.
Classically, ALI has been described as progressing
through three stages: exudative, proliferative, and ﬁbrotic
[8, 9]. Although diﬀerent mechanisms of lung injury and
severity of illnesses signiﬁcantly inﬂuence the severity and
duration of these stages [10], the three-stage model has
remainedlargelyintactforfourdecadesandservesasauseful
frame of reference for discussion.
Exudative. this initial stage of ALI encompasses the ﬁrst
seven days of illness and is marked by a net eﬄux of
proteinaceous material from the intravascular to the alveolar
spaces. By deﬁnition this eﬄux is related to increased capil-
lary permeability (i.e., a reduced reﬂection coeﬃcient) and
not hydrostatic forces (i.e.,an elevated left atrial pressure).
The alveolar exudate reduces lung compliance and increases
alveolar surface tension both by virtue of the increased
viscosity of the exudate compared to air and by pulmonary
surfactant neutralization [11–13]. As vascular leak occurs to
varyingdegrees,lungcomplianceisheterogeneousleadingto
focal areas of atelectasis and the patchy bilateral inﬁltrate on
chest X-ray classic of ALI. With positive pressure ventilation,
this heterogeneous lung compliance leads to relative overdis-
tention of more normal alveolar units and underinﬂation of
lower compliance ones. Perfusion of inadequately ventilated
lung units leads to pulmonary venous desaturation and the
hypoxemia of ALI.2 Advances in Pharmacological Sciences
Table 1: Diagnostic Criteria for ALI and ARDS [6].
ALI Criteria ARDS Criteria
Acute Onset Acute Onset
PaO2/FiO2 ≤ 300 mmHg PaO2/FiO2 ≤ 200 mmHg
Chest Radiograph: Bilateral
inﬁltrates
Chest Radiograph: Bilateral
inﬁltrates
No evidence of left atrial
hypertension
No evidence of left atrial
hypertension
Proliferative. this second stage is a pathological ﬁbroprolif-
erative response to the initial injury and is classically deﬁned
as occurring during the second week. Until recently, endoge-
nous ﬁbroblasts were thought to mediate this response;
however, emerging evidence suggests that transformation
of injured epithelial cells to ﬁbroblast-like cells (epithelial-
mesenchymal transition) may play a prominent role [14].
ALI resulting from diﬀerent mechanisms of injury has also
been associated with the presence or absence of myoﬁ-
broblasts [15, 16]. As myoﬁbroblasts exhibit a substantially
enhanced ﬁbroproliferative response to cytokines such as
transforming growth factor-β [17, 18], there may be a role
for cytokine antagonism in these patients. Regardless of
ﬁbroblast origin or phenotype, the lung’s ability to turn oﬀ
the ﬁbroproliferative response and begin tissue remodeling
is a critical determinant of outcome.
Fibrotic. two to three weeks following the initial injury,
the lung parenchyma either undergoes tissue remodeling
leading resolution or the ﬁbroproliferative response is not
turned oﬀ and ﬁbrosis results. Patients who initiate lung
remodeling typically will have near-normalization of pul-
monary function six months later [19]. Patients who fail
to initiate lung remodeling experience progressive ﬁbrosis
which leads to worsening respiratory insuﬃciency and death
weekstomonthslater.Intheadultpopulation,somepatients
experience initial improvement in lung function only to
develop idiopathic pulmonary ﬁbrosis months to years
later. Idiopathic pulmonary ﬁbrosis also leads to progressive
respiratory insuﬃciency and death over the course of several
months to several years [20].
3. Nonpharmacologic Therapies for ALI
ThereisnocureforALI.Treatmentisentirelysupportiveand
aimstomaintainadequateoxygenationandventilationwhile
minimizing secondary lung injury. The strategies by which
this is done are brieﬂy outlined below.
3.1. The Lung Protective Strategy. The “Lung Protective
Strategy” refers to three interventions intended to min-
imize secondary lung injury in patients with ALI who
require mechanical ventilation. These interventions are (1)
reduction of tidal volumes (volutrauma), (2) minimization
of airway pressures (barotrauma), and (3) application of
the minimum end expiratory pressure to prevent airway
collapse (atelectrauma) [21]. A large multicenter study on
ARDS showed that a 6mL/kg tidal volume resulted in a
9% reduction in mortality compared to a 12mL/kg volume
[22]. The use of high PEEP-low fractional inspired oxygen
[23], oscillatory ventilation [24, 25], or newer ventilator
modes such as airway pressure release ventilation [26]
have not been shown to improve mortality. There is no
mortality data available on other ventilator modes such
as neurally adjusted ventilator assist (NAVA) or volume
support ventilation, although these modes (as well as others)
have shown improvements in secondary outcomes such as
oxygenation, duration of mechanical ventilation, or patient-
ventilator synchrony [27].
3.2. Alveolar Recruitment. By virtue of the heterogeneous
compliance seen in ALI, positive pressure ventilation results
in overdistention of lower compliance areas of lung and
underinﬂation of others. Maximizing alveolar recruitment
shouldminimizethesedisparities.“Recruitmentmaneuvers”
refertoseveraltechniquesthatincreasemeanairwaypressure
temporarily to open closed alveoli. Prone positioning rere-
cruits dependent lung segments. Both recruitment maneu-
vers [28] and prone positioning [29, 30] have been shown to
improve oxygenation but not survival.
3.3. Fluid Management Strategies. Adequate ﬂuid resusci-
tation is a key determinant of survival in septic shock.
However, ﬂuid-overload has been associated with poorer
outcomes in ALI [31]. In a recently completed randomized
trial comparing liberal to restrictive ﬂuid management after
initial resuscitation, patients in the restrictive arm had
signiﬁcantly reduced duration of mechanical ventilation and
reduced intensive care stay but no reduction in mortality
[32]. Furosemide was part of the management algorithm
of this trial (FACTT). To date, no trial has investigated the
isolated use of furosemide in ALI, but combining albumin
replacement with furosemide administration in the context
of hypoproteinemia improved ﬂuid balance and oxygenation
but not mortality [33, 34]. There is an emerging consensus
that after initial resuscitation, achieving a negative ﬂuid
balanceisimportantinimprovingoutcomesinsepsis-related
ALI [35].
3.4. Extracorporeal Membranous Oxygenation. The use of
ECMO in ALI is associated with survival in 57% of pediatric
patients [36]; however, disappointing results in two early
adult trials dampened enthusiasm in that population [37,
38]. A recent adult trial randomizing patients with severe
ARDS to standard of care at the admitting facility versus
transfer to a single ECMO center showed better outcomes
in those treated with ECMO; however, no diﬀerence in
outcomes was noted between the ECMO group and the
conventional ventilation group at the referral center [39].
Whether the increased use of ECMO in adults seen during
the H1N1 inﬂuenza pandemic [40] persists is yet to be seen.
3.5. Pumpless Extracorporeal Oxygenation and Carbon Diox-
ide Removal. In patients with adequate cardiac output,
extracorporeal oxygenation and CO2 removal devices canAdvances in Pharmacological Sciences 3
reduce the ventilator work required to maintain acceptable
PaO2 and PaCO2 levels. There is currently no FDA-approved
device for this indication; however, several are approved for
u s ei nC a n a d aa n dE u r o p e .T h ed e v i c e sh a v ea na d v a n t a g e
over traditional extracorporeal membranous oxygenation
in that they require less anticoagulation and cause less
hemolysis [41, 42].
4. Pharmacologic Therapies for ALI
The history of pharmacologic treatments for ALI is marked
by many therapies that showed beneﬁt in animal and small
human trials but failed in larger human trials. Whether
this is due to our inability to identify ALI subgroups or
the immutability of ALI pathophysiology is a matter of
conjecture.
4.1. Corticosteroids. The use of corticosteroids for ALI has
been the subject of multiple trials [43–47] with one of them
being a multicenter randomized trial [47]. The therapeutic
rationale for their use is to blunt ﬁbroproliferation. Many
dosing regimens of corticosteroids have been reported, but
the regimen in the largest trial [47] used a 2mg/kg loading
dose of solu-medrol, 0.5mg/kg every 6 hours for 14 days,
0.5mg/kg every 12 hours for 7 days, and then a taper
dependent on the patient’s clinical status. In the above
trial, the intervention group experienced improvements in
oxygenation and ventilator-free days, but no improvement
in mortality. However, on subset analysis, there was a
signiﬁcantly increased risk of mortality in patients given
solumedrol more than 14-days after ARDS onset and a
trend towards improved mortality in those treated 7–14
days from ARDS onset. A meta-analysis of patients treated
with corticosteroids before day 14 showed improvement in
outcomes [48]. A trial from the same authors suggested
beneﬁt in starting corticosteroids within 72 hours of ARDS
onset [45]. No trials have been performed to compare
timing of initiation, dosing, or duration of drug admin-
istration. Particularly in the context of sepsis, early, high-
dose steroid administration may slow pathogen clearance,
induce myopathy, increase the risk of secondary infections,
and slow wound healing. The literature supports the use of
corticosteroids in ALI prior to 14 days from ALI onset. Their
use should be considered in this context after a careful risk-
beneﬁt analysis.
4.2. β2-Agonists. Apart from their bronchodilator prop-
erties, β2-receptor signaling increases alveolar type-I cell
aquaporin-5 expression and aids in alveolar ﬂuid reab-
sorption [49]. In vitro, ex vivo, and preliminary human
studies suggest that β2-agonist therapy increases alveolar
ﬂuid reabsorption and improves lung compliance [50–53].
A large randomized trial using aerosolized albuterol every 4
hours in mechanically ventilated adult patients with ARDS
was terminated for futility. However, a smaller randomized
trial using salbutamol infusion improved lung water and
plateau airway pressures [54],leading some to speculate
that inadequate drug delivery may have blunted therapeutic
beneﬁt in the larger trial.
4.3. Furosemide. Independent of its diuretic actions, fu-
rosemide has been shown in animal studies to improve lung
function in ALI [55]. This may be secondary to the anti-
inﬂammatory eﬀects of furosemide, particularly its ability to
reduce tumor necrosis factor-α levels [56].
4.4. Neuromuscular Blockade. Neuromuscular blockade us-
ing nondepolarizing agents is highly associated with the
development of ICU myopathy, particularly in the adult
population [57]. In combination with sedation and anal-
gesia, they are generally used to facilitate ventilation and
oxygenation in the most severe cases of ARDS. However,
a recent single-center trial has suggested some intrinsic
beneﬁt of neuromuscular blockade in the ﬁrst 48 hours of
mechanical ventilation with increased ventilator-free days
and reduced time in the ICU [58]. The mechanism by which
this occurs is unclear.
4.5. Surfactant Replacement Therapy. Pulmonary surfactant
improves pulmonary compliance by reducing alveolar sur-
face tension in lower compliance alveoli thus promoting
more uniform alveolar inﬂation. Surfactant replacement
therapy is clearly beneﬁcial in premature neonates with
respiratory distress syndrome [59, 60] and also beneﬁts
neonateswithlunginjurysecondarytoinfections[61].Large
randomized studies using surfactant replacement in adults
have been unequivocally negative and some have tended
towards harm [62–65]. Several factors may account for these
diﬀerences.
(1) Infants, particularly premature infants appear to
be surfactant-dependent to maintaining alveolar
recruitment. A normal adult has a surfactant pool
size of about 22mg of phospholipid per kg. An infant
withoutRDShasapoolsizeofabout60mg/kgandan
infant with RDS has a pool size of less than 15mg/kg
[66]. Surfactant depletion is a negative predictor of
extubation success in premature infants [67].
(2) The developing lung does not begin alveolarization
until approximately 35 weeks after conceptional age
[68], and alveolarization continues through toddler-
hood [69]. Pores of Kohn (alveolar) and Canals of
Lambert (bronchiolar) develop at approximately one
and ﬁve years of age respectively and contribute sub-
stantially to the maintenance of alveolar recruitment
in the context of lung injury [70]. The lung therefore
becomes able to maintain alveolar recruitment with
progressively less surfactant with improved alveolar
development.
(3) The leak of serum proteins into the alveolar space
leads to surfactant inactivation in ARDS [13],
whereas the principle problem in RDS is surfactant
deﬁciency.4 Advances in Pharmacological Sciences
Controversy exists as to whether or not surfactant
replacement is helpful in the pediatric population. A single-
center trial [71] and multicenter trial [72] in pediatrics
showed improvements in mortality and ventilator-free days
respectively with the most beneﬁt seen in patients with
primary lung infections, but both the adult and pediatric
arms of a large multi-center trial using calfactant were
ended early for futility. Several reviews on beneﬁts and
shortcomings of the diﬀerent surfactant preparations are
available [73, 74]. The clinical utility of diﬀerent surfactant
preparationsisthesourceofmuchdebateamongproponents
and opponents of this therapy [75].
4.6. Inhaled Nitric Oxide. Nitric oxide (NO) is a free-
radical with a half-life of a few seconds produced by several
diﬀerent isoforms of nitric oxide synthase throughout the
body. It is a potent pulmonary vasodilator and is currently
FDA approved for use in pulmonary hypertension [76]. In
conditions in which there is a large degree of pulmonary
shunting (such as ALI), theoretically, inhaled NO may be
used to increase pulmonary blood ﬂow to ventilated units
and improve ventilation-perfusion matching. In addition,
some clinicians believe that NO may treat the secondary
pulmonary hypertension seen in ALI. A recently conducted
meta-analysis on the use of inhaled nitric oxide in adults
and children with ALI, including fourteen randomized
control studies, concluded that inhaled nitric oxide improves
oxygenation but does not reduce length of ventilation, ICU
stay, or mortality [77]. The general use of NO for ALI should
be discouraged, although it may beneﬁt a subset of patients
with ALI.
4.7. Ω-3 Fatty Acids. Oxidative damage due to high frac-
tionalinspiredoxygenisthoughttobeasubstantialsourceof
continued injury in ALI. Ω-3 fatty acids possess antioxidant
properties and animal and small human trials administering
supplemental Ω-3 fatty acids showed improvement in out-
comes [78, 79]; however, a large randomized trial using an
Ω-3fortiﬁedenteralformulawasterminatedearlyforfutility.
Many confounders in the trial such as feeding intolerance, a
low-mortality rate in the control group, and use of a fortiﬁed
formula instead of supplements may lead to further studies
in this area.
4.8. Liquid Ventilation. Perﬂuorocarbons are inert, low-
surface tension liquids that have a high oxygen-carrying
capacity. They may be used either to ﬁll the lungs partially or
completely. When they are used to ﬁll the lungs completely
(tidal liquid ventilation), liquid in a reservoir is oxygenated
and cycled through the lung by active inspiration and
exhalation. Traditional ventilation is used in partial liquid
ventilation and the perﬂourocarbons act as a surfactant
with the beneﬁt of having high gas solubility coeﬃcients
[80]. Case series demonstrate the feasibility of using liquid
ventilation in neonates [81–84], but it showed neither
beneﬁt nor harm in industry-sponsored adult trials. Further
investigations are required before making recommendations
regarding its use [85].
4.9. Activated Protein C. Multisystem organ failure (MSOF)
is a common consequence of sepsis with the lung being
one of the ﬁrst organ systems typically involved. The
pathophysiology of MSOF is complex but involves the
development of diﬀuse microvascular thrombosis leading to
local ischemia, cellular dysfunction, and cell death. Protein C
is an endogenous anticoagulant that cleaves activated factors
V and VIII. Levels are often pathologically low in sepsis [86].
A large multicenter randomized trial involving adult and
pediatric patients with sepsis found a small but signiﬁcant
improvement in mortality in adults with a moderate organ
dysfunction, but the pediatric arm of the trial was stopped
earlyduetobleedingcomplications[87].Theuseofactivated
protein C speciﬁcally for ALI is still in the preclinical phase
[88].
4.10. Mesenchymal Stem Cells. MSCs are nonhematopoietic
progenitorcellsidentiﬁedbyahostofsurfacemarkers,reside
in the bone marrow, and display a ﬁbroblast-like phenotype
in cell culture. MSCs were found safe in a Phase I trial
of patients with acute myocardial infarction with patients
receiving the MSCs having faster resolution of symptoms
[89] and have shown promise in improving survival in
sepsis [90] and acute kidney [91] injury among other
conditions. Animal models of lung injury suggest that either
intravascular [92, 93] or intratracheal [94] administration of
MSCs improve lung function. Despite early concerns about
engraftment [95], it now appears that although these cells
traﬃc to the lung interstitium they do not exhibit long-term
engraftment [93]. A human trial using MSCs in adults with
severe ARDS is currently being developed.
5. Conclusions
ALI is a common complication of sepsis. Despite multiple
trials, the only therapy that has demonstrated clear beneﬁt
with regards to mortality is the employment of low tidal vol-
ume ventilation strategy. Although no mortality beneﬁt was
demonstrated, a restrictive ﬂuid strategy is well supported.
Arguably, only two drugs, solumedrol and furosemide,
have shown therapeutic beneﬁt. Among the other therapies
listed, their general use cannot be advocated but may be
beneﬁcial to select patients. We do not yet have the ability
to phenotype ALI in a clinically meaningful way. As ALI is
common in ICUs and associated with signiﬁcant morbidity,
mortality,andcost,investigatorswillcontinuetoexplorenew
pharmacologic and nonpharmacologic therapies despite a
long history of disappointments.
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